ASCO 2009 -Omacetaxine active w/minimal toxicity in T315i positive CML patients who failed imatinib

Capsule Summary
CCO-Independent Conference Coverage of the

American Society of Clinical Oncology Annual Meeting, June 2009*

Omacetaxine Active With Minimal Toxicity in T315I-Positive CML Patients Who Failed Imatinib
Posting Date: June 03, 2009
o Ongoing, non-randomized phase II/III trial[1] Omacetaxine, a first-in-class cetaxine, resulted in durable hematologic and cytogenetic responses in patients with T315i positive chronic myeloid leukemia (CML) who had previously failed imatinib therapy

Summary of Key Conclusions

o Generally well tolerated o Potential for patients to self-administer o Most common toxicity: myelo-suppression
Hematologic Malignancies In this Expert Recap, Edward A. Stadtmauer, MD, discusses the most important studies in multiple myeloma, lymphomas, and leukemias, as presented at the 2009 Clinical Oncology meeting.